Hearing loss and COVID-19: an umbrella review. | Canada Hyperbarics Skip to main content
Review European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - 2023

Hearing loss and COVID-19: an umbrella review.

Mehraeen E, Afzalian A, Afsahi AM, Shahidi R, Fakhfouri A, Karimi K, et al. — European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - , 2023

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers conducted an umbrella review to investigate the manifestation of hearing loss associated with COVID-19.

What They Found

The review identified four treatment strategies, including oral corticosteroids, intratympanic corticosteroids, combined therapy, and hyperbaric oxygen therapy. Of five studies examining corticosteroid use, four reported complete or partial hearing improvements, while one study found no significant improvement in hearing function.

What This Means for Canadian Patients

Canadian patients experiencing hearing loss after COVID-19 should discuss potential treatment options, such as corticosteroids, with their healthcare provider. Early consultation may help address these otologic symptoms.

Canadian Relevance

This study has no direct Canadian connection.

Study Limitations

A limitation of this umbrella review is the potential for heterogeneity and varying quality among the included studies.

Was this summary helpful?

Study Details

Study Type Review
Category Neurological
Source Pubmed
PubMed ID 37093291
Year Published 2023
Journal European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology -
MeSH Terms Humans; Hearing Loss, Sudden; Quality of Life; COVID-19; Hearing Loss, Sensorineural; Adrenal Cortex Hormones; Deafness; Injection, Intratympanic; Treatment Outcome; Dexamethasone; Glucocorticoids

Cite This Study

Share
Discuss with a qualified healthcare professional. Then: Review Coverage Guide View Recognised Conditions

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.